Tranexamic
acid is increasingly being used to prevent postpartum haemorrhage (blood loss
of over 500 ml or 1,000 ml within 24 hours of childbirth) due to its cheap
price and wide availability. Tranexamic acid is an antifibrinolytic drug that
helps in reducing bleeding in surgical and trauma patients, including women
with postpartum haemorrhage. In April 2017, WOMAN (World Maternal
Antifibrinolytic), an international, randomized, double-blind,
placebo-controlled trial including over 20,000 women from 193 hospitals in 21
countries, found that using tranexamic acid within three hours of childbirth
lowered death from bleeding by 31% and reduced the need for laparotomy
(emergency bleeding control surgery) by 36%, as compared to placebo.
THE BUSINESS RESEARCH COMPANY EXPECTS THE GLOBAL HEMATOLOGY
DRUGS MARKET TO GROW TO $52 BIILLION BY 2021
North
America was the largest region in the haematology drugs market in 2017, accounting for more than one-third of the market share. This
was mainly due to established healthcare market coupled with nationwide health
insurance coverage in countries such as the USA and Canada.
Order the report at: https://www.thebusinessresearchcompany.com/report/hematology-drugs-global-market-report-2018
The chart below shows
the year-on-year growth of the global haematology
drugs market during 2017-2021
According to The
Business Research Company’s Consultant, Nitin Gianchandani, the use of gene
therapy to treat sickle-cell disease is gradually increasing due to its
simplicity, as compared to procedures requiring outside donors. Sickle-cell
disease is a type of gene disorder in which a genetic mutation causes
hemoglobin in the red blood cells to distort the shape of the cell. This leads
to aggregation or clogging of blood resulting in further acute and chronic
complications. In gene therapy, a patient serves as his own donor which
eliminates the risk of a mismatch.
Download a
sample of the report at:
Novo Nordisk A/S
was the largest player in the hematology drugs market in 2017, with revenues of
$3.4 billion in 2016. Novo’s growth strategy is to expand its hematology
business by developing new drugs for treatment of hematologic disorders.
The hematology
drugs market offers drugs, blood and blood products that are used for the
treatment of diseases such as rare genetic disorders, anaemia, and conditions
related to sickle cell disease and other related diseases.
Hematology
Drugs Global Market Report 2018 is
a detailed report giving a unique insight into this market. The report is
priced at $4000 for an individual user. To use across your office, the price is
$6000 and $8000 if you wish to use across a multinational company.
About The Business Research Company:
Visit
TheBusinessResearchCompany.com, mail info@tbrc.info or
call +447443439350 or +918897263534 or +919160996838 for more information on
this and many other titles.
The
Business Research Company is a market research and intelligence company, which
excels in company, market and consumer research.
It has
research professionals at its offices in the UK, India and the US as well a
network of trained researchers globally. It has specialist consultants in a
wide range of industries including manufacturing, healthcare, chemicals and
technology.
The
Business Research Company's management has more than 20 years of varied
business research experience. They have delivered hundreds of research projects
to the senior management of some of the world's largest organizations.
Contact
Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
No comments:
Post a Comment